Additionally, PAH combination therapy (all cases were a combination of a PDE5 inhibitor and an ERA) also showed a trend towards a survival benefit compared with monotherapy alone (p = 0.10). The gene discussed is PDE5A; the disease is pulmonary arterial hypertension.